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INTRODUCTION
Cerebrospinal meningitis, also called epidemic
meningococcal meningitis, is a major public health
problem still affecting tropical countries, particularly
in sub-Saharan Africa. It is highly contagious and
mortality from the disease remains high, despite major
achievements in the treatment modalities. It is reported
that 4 – 17% of patients die despite treatment.1, 2
Neisseria meningitidis has 13 known serotypes
worldwide with groups A, B and C being the
commonest cause of diseases worldwide.3 Groups
A, B, C, Y, and W-135 are responsible for most of
invasive disease in both developed and developing
countries, whereas, group A and occasionally group
C account for large scale epidemics in many countries
particularly in sub-Saharan Africa.4, 5 The African
meningitic belt region comprises of 25 countries
stretching from Senegal to Ethiopia with a total
population of about 500 million people).6
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In the African meningitis belt, and specifically within
northern Nigeria, most meningitis outbreaks have been
caused by N. meningitides serogroup A (NmA).2, 7-10 A
particularly severe epidemic of meningococcal
meningitis occurred in Nigeria between January and
June 1996, with 109,580 recorded cases and 11,717
deaths, with a case fatality rate of 10.7%. This was the
most serious epidemic of CSM ever recorded in
Nigeria, and may be the largest in Africa this century.11
It took over 3 months and the combined efforts of a
National Task Force set up by the Federal Ministry of
Health, the World Health Organization (WHO), United
Nations Children Fund (UNICEF), United Nations
Development Fund (UNDP), Médecins Sans
Frontières (MSF), the International Red Cross and
several other non-governmental organizations to bring
the epidemic under control.11
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Nigeria with support from the Global Alliance for
Vaccine Initiative (GAVI) introduced MenAfriVac– a
vaccine which protects against the most prevalent type
of Nm serogroup A. Mass campaigns was carried
out in all CSM high risk states including Kebbi state
with the expectation that it would prevent more than
150,000 deaths by 2015 as well as avoid significant
disability and have considerable economic benefits.6
In the past 15 years, there has been increasing number
of large outbreaks caused by N. meningitidis serogroups
W135 and X in Niger, Burkina Faso and northern
Ghana.7 Outbreaks due to Neisseria meningitidis
serogroup C (NmC) have also occurred but were
smaller and less frequent than NmA outbreaks.2, 10 The
last NmC outbreak in this region occurred in 1979 in
Burkina Faso with 539 cases reported (attack rate (AR)
517/100,000).7 Outbreaks caused by NmC in northern
Nigeria are rare, with the last and only recorded
outbreak in 1975 with no detailed report published.
Other notable NmC outbreaks occurred in the 1970s
in Sao Paulo, Brazil and Ho Chi Minh, Vietnam with
2005 (11/100,000 people) and 1015 (>20/100,000
people) cases respectively.7 In the USA, morbidity and
mortality are higher among young adults in outbreaks
caused by NmC compared with other serogroups.7
Nigeria has not recorded any major outbreak of
meningitis since 2012 because of the introduction of
MenAfriVac vaccine in December 2011. In 2011, 7.4
million eligible Nigerians were immunized, in 2012
another 7.5 million and in 2013 yet another 7.8 million.
Because of this, no major outbreak of meningitis has
been experienced. The vaccination offers a minimum
of 10 years protection to maximum of lifelong
protection.6 In response to meningitis A (NmA)
outbreak that occurred in Sokoto and Kebbi states
between 2008 and 2009, Médecins sans Frontières
(MSF) conducted reactive vaccination using
polysaccharide ACYW135 vaccine.7 There has been
no mass vaccination specifically targeting NmC alone
in this region.7 This paper describes the general
characteristics of an outbreak due to a strain of NmC
in Kebbi State, Nigeria in 2015.
MATERIALS AND METHODS
Study area
Kebbi state, located in Northwestern Nigeria and lies
in the African meningitis belt. Outbreaks of meningitis
were a usual occurrence until 2010 when MenAfriVac
(vaccination against Meningitis serogroup A) was rolled
out and outbreaks in the state stopped. The state has
21 local government areas (LGAs) each with a General
hospital and a network of Primary health centres
(PHCs) in almost all wards. Each LGA has a Disease
Surveillance and Notification Officer (DSNO) who
is responsible for collating data from the ward focal
person stationed in each ward. There is also a Federal
Medical Centre located in the state capital.
Study design
The study design is a descriptive secondary data analysis.
During this outbreak, the following case definitions
were used:
Suspected meningitis case: Any person with sudden
onset of fever (>38.5 C rectal or 38.0 C axillary) and
one of the following signs: neck stiffness, altered
consciousness or other meningeal signs.
Any toddler with sudden onset of fever (>38.5 C rectal
or 38.0 C axillary) and one of the following signs:
neck stiffness, or flaccid neck, bulging fontanel,
convulsion or other meningeal signs.
Probable meningitis case: Any suspected case with
macroscopic aspect of its CSF turbid, lousy or
purulent; or with microscopic test showing Gram
negative diplococcus, Gram positive diplococcus,
Gram positive bacillus; or with leukocytes count more
than 10 cells/mm3.
Confirmed meningitis case: Isolation of  the causal
pathogens (N. meningitidis, Streptococcus pneumoniae,
Haemophilus Influenzae b) from the CSF of a
suspected/probable case or by haemoculture or PCR.
Data collection
Ward focal persons working in health facilities are
responsible for collating Meningitis surveillance data.
Disease surveillance and notification officers (DSNOs)
contacted all health posts in their jurisdiction each week
and linked suspected cases to the treatment camps for
investigation and treatment. Information on cases and
deaths was collected using a standard line-list during
each week of  the meningitis outbreak. Information
collected included patients age, sex, residence, signs
and symptoms, date of start of symptoms, medication
received before presentation. At health camps,
information for each case was recorded in a
standardized line-list. Cerebrospinal fluid specimen was
taken from 75 (3.8%) patients for analysis. Initial
serogroup confirmation was by rapid Pastorex
agglutination tests. Cerebrospinal fluid samples from
suspected meningitis patients were sent to the Reference
Laboratory where bacterial isolates, serogrouping and
antimicrobial sensitivity testing were performed.
Data analysis
All line-listed data were entered into Microsoft Excel
and SPSS version 20.0. Data editing was performed
by running frequencies and descriptive statistics for all
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variables to check for incompletely filled data which
was excluded from analysis. Median age and age range
was calculated (non-parametric data). Frequency
tabulation was done for all the variables namely; age,
sex and geographical distribution. An epidemiological
curve showing the time trend of  the cases was also
done using excel. The proportion of cases immunized
against meningitis, proportion from whom CSF
specimen was taken and proportion positive from
testing were all tabulated.
RESULTS
Socio-demographic data
From the 5th to the 22nd epidemiologic week of 2015,
1,992 suspected cases of CSM were seen and managed
at various health facilities in the state. One thousand
one hundred and twenty seven (57%) of cases were
males while 865 (43%) were females giving a male:
female ratio of  1.3: 1 (Table 1). The highest
proportions of cases were found in those above 15
years of age (31.0%), 10 - 14 years (27.7%) and the 5
– 9 years (27.4%) (Table 1). Sixteen (16) of  23 LGAs
in Kebbi state (two-thirds of the LGAs) reported cases
and Aliero LGA had the highest number of cases seen
(55.5%) (Table 1).
Epidemiologic data
An epidemic curve drawn showed that it was a
propagated epidemic with bimodal peaks. The initial
peak was in the 8th week (n=253 cases) and a second
peak in the 13th week (n=304 cases) (figure 1). One
thousand two hundred and fifty two (62.9%) of the
cases had received vaccination against Nm type A within
the last 3 years prior to the outbreak (Table 2). Fifty
eight (77.3%) of the 75 CSF samples taken from cases
were positive for Nm serogroup type C (Table 2).
Five (6.7%) of which were either inadequate in quantity
or had spilled and were unsuitable for laboratory
analysis (Table 2). Eighty (80) deaths were recorded
from the treatment centres giving a case fatality rate
(CFR) of  4.0% (Table 2).
Variable Number (n = 1992) Percent
Age group
< 1 year 13 65.3
1 – 4 years 261 13.1
5 – 9 years 546 27.4
10 – 14 years 552 27.7




















Koko/ Besse 2 0.1
Fakai 1 0.1
Table 1: Socio-demographic characteristics of  the cases
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DISCUSSION
Meningococcal meningitis is primarily a disease of
young children, but in epidemics, a variety of clinical
presentations may be seen. This data shows a relative
sparing of the under 5 year olds as only 13.8% of
cases belonged to this age group. This finding is similar
to previous but smaller outbreaks in neighbouring Yabo
and Silame LGAs of Sokoto state in 2013 - 2014.7 It
is also similar to findings from another outbreak in
Gusau, Zamfara state where majority of cases were
among the 5 – 14 years and the 15 – 29 years age
group.12 The much higher presentation seen in older
children and adults in recent epidemics may be worth
taking up as a research problem to be investigated in
subsequent researches.
Outbreaks of Neisseria Meningitides (Nm) type C has
been on the increase since 2013 in Sokoto and Kebbi
states in Northwest, Nigeria.7 Eight hundred and fifty
six (856) cases were reported in Sokoto state in 2013
with a case fatality rate (CFR) of 6.8%. Kebbi state
had less than 200 cases in 2013, 333 cases with a CFR
of  10.5% in 2014.7 The 2015 figure gives an alarming
5 fold rise in the number of cases seen compared to
that of 2014. This implies it could get worse in
subsequent years if no public health measures are put
in place to stop the trend.
The case fatality rate for 2015 (4.0%) was less than
half that of 2014 (10.5%) though it involved more
than twice the number of deaths reported in 2015 (80
Variable Number Percent
Received vaccine (n = 1992)
Yes 1252 62.9
No 740 37.1
CSF specimen taken (n = 1992)
Yes 75 3.8
No 1917 96.2




Outcome of cases (n = 1992)
Alive 1912 96.0
Dead 80 4.0
Table 2: Vaccination, CSF and outcome of  treatment characteristics of  cases
Figure 1: Distribution of cases of CSM by week of onset in Kebbi state in 2015
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deaths) when compared to 2014 (35 deaths). The
relatively lower CFR in 2015 was possibly due to the
effect of health education/promotion messages given
to affected communities and the state as a whole via
the mass media during the 2014 outbreak. This led to
better health seeking behavior at treatment centres in
2015 and therefore the relatively better health outcomes.
Strengthening the surveillance system to make it more
effective (sensitive and specific) and giving DSNOs
and healthcare workers refresher training on how to
promptly identify Meningitis cases will further help in
reducing Meningitis burden. The case definitions of
Meningitis should be conspicuously displayed at health
facilities to help health workers identify cases.
Outbreaks of NmC in Nigeria are rare, the most
recent documented outbreak of this serotype in
Northern Nigeria was in 1975 before its resurgence in
2013. There is a possibility of emergence of new strains
or less commonly seen serogroups such as NmC
following mass vaccination campaigns against a
particular serogroup. In this case MenAfriVac a
conjugate vaccine against serogroup “A” was used for
vaccination campaigns between 2012 and 2013 in
Kebbi state.7 Serogroup replacement following mass
meningitis vaccination has been noted in West Africa;
reports from Niger republic and Burkina Faso have
indicated a significant increase in serogroup W135
prevalence in the years following campaigns with
MenAfriVac® around 2010.13, 14 More recently in
Nigeria mass vaccination campaigns with monovalent
oral polio vaccine against (OPV1) led to an outbreak
of the less common wild polio virus type 3 (WPV3).
This necessitates the need for the use of multivalent
vaccines especially in scenarios where more than one
serogroup has epidemic potential and the need for
strengthening instituted enhanced surveillance systems.
CONCLUSION
Kebbi state has experienced seasonal outbreaks of
cerebro-spinal Meningitis (serogroup Nm C) since
2013 with a massive outbreak in 2015. Mass vaccination
campaigns have been carried out in previous years
against Nm A (MenAfriVac) with about two thirds
of the cases immunized. There is a need to vaccinate
vulnerable populace with polyvalent vaccines containing
serogroup C to prevent future occurrence.
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